Chewy, Inc. (CHWY)
NYSE: CHWY · Real-Time Price · USD
35.91
-0.79 (-2.15%)
At close: Aug 1, 2025, 4:00 PM
35.75
-0.16 (-0.45%)
After-hours: Aug 1, 2025, 7:43 PM EDT
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 21 analysts that cover Revance Therapeutics stock have a consensus rating of "Buy" and an average price target of $43.57, which forecasts a 21.33% increase in the stock price over the next year. The lowest target is $28 and the highest is $52.
Price Target: $43.57 (+21.33%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Revance Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 6 | 6 | 6 | 6 | 6 |
| Buy | 11 | 11 | 11 | 11 | 11 | 12 |
| Hold | 5 | 6 | 6 | 6 | 8 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 23 | 23 | 23 | 25 | 25 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JMP Securities | JMP Securities | Buy Maintains $39 → $48 | Buy | Maintains | $39 → $48 | +33.67% | Jul 10, 2025 |
| Jefferies | Jefferies | Hold Maintains $43 → $44 | Hold | Maintains | $43 → $44 | +22.53% | Jun 12, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $39 → $50 | Buy | Maintains | $39 → $50 | +39.24% | Jun 12, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $42 → $44 | Buy | Maintains | $42 → $44 | +22.53% | Jun 12, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $42 → $45 | Strong Buy | Maintains | $42 → $45 | +25.31% | Jun 12, 2025 |
Financial Forecast
Revenue This Year
12.76B
from 11.86B
Increased by 7.61%
Revenue Next Year
13.73B
from 12.76B
Increased by 7.54%
EPS This Year
0.55
from 0.91
Decreased by -39.08%
EPS Next Year
0.81
from 0.55
Increased by 46.83%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 14.2B | 15.4B | 16.4B | ||
| Avg | 12.8B | 13.7B | 14.8B | ||
| Low | 12.1B | 12.9B | 13.6B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 19.7% | 20.3% | 19.2% | ||
| Avg | 7.6% | 7.5% | 8.1% | ||
| Low | 2.4% | 1.0% | -0.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.31 | 1.58 | 1.33 | ||
| Avg | 0.55 | 0.81 | 1.09 | ||
| Low | 0.43 | 0.60 | 0.91 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 44.2% | 184.1% | 63.8% | ||
| Avg | -39.1% | 46.8% | 33.7% | ||
| Low | -52.6% | 7.8% | 12.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.